Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell”

Seres Therapeutics (NASDAQ:MCRB) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other brokerages also recently issued reports on MCRB. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Performance

Shares of MCRB opened at $0.84 on Friday. The stock has a 50 day moving average price of $0.83 and a two-hundred day moving average price of $0.90. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The firm has a market capitalization of $144.15 million, a P/E ratio of -3.67 and a beta of 2.13.

Hedge Funds Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MCRB. FMR LLC grew its holdings in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Seres Therapeutics in the third quarter worth $374,000. Finally, State Street Corp increased its stake in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 43,700 shares during the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.